Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study

Safety and effectiveness of daily teriparatide for osteoporosis in patients with severe stages of chronic kidney disease: post hoc analysis of a postmarketing observational study

Atsushi Nishikawa,1 Fumito Yoshiki,2 Masanori Taketsuna,2 Kenta Kajimoto,2 Hiroyuki Enomoto2 1Global Patient Safety Japan, Quality and Patient Safety, Eli Lilly Japan K.K., 2Medicines Development Unit Japan, Eli Lilly Japan K.K., Kobe, Japan Abstract: Teriparatide (recombinant 1–34 N-ter...

Full description

Bibliographic Details
Main Authors: Nishikawa A, Yoshiki F, Taketsuna M, Kajimoto K, Enomoto H
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:Clinical Interventions in Aging
Subjects:
Bone Mineral Density
Chronic Kidney Disease
Fragility Fracture
Parathyroid Hormone
Teriparatide
Safety.
Online Access:https://www.dovepress.com/safety-and-effectiveness-of-daily-teriparatide-for-osteoporosis-in-pat-peer-reviewed-article-CIA

Internet

https://www.dovepress.com/safety-and-effectiveness-of-daily-teriparatide-for-osteoporosis-in-pat-peer-reviewed-article-CIA

Similar Items